Mounjaro's titration schedule looks simple on the box: five dose increases over roughly five months. In practice it is the part of a tirzepatide service that goes wrong most often, because every step-up is a fresh judgement about tolerability, not just a date on a calendar. Getting the operational side right matters as much as the prescribing itself.
What the Mounjaro titration schedule actually involves
Mounjaro's licensed dosing runs in fixed strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, given as a once-weekly injection, with each step-up spaced at least four weeks apart. The schedule sets a minimum interval between increases, not a fixed one, and the pace above that minimum is a prescriber decision, not an automatic default.
The starting dose, 2.5mg, is there to let the body adjust rather than to produce meaningful weight loss on its own. Most of the clinical benefit builds once a patient has stepped up to 5mg and beyond, which is exactly why a titration pathway needs treating as a structured sequence of decisions, not a single prescribing event that happens once at the start.
Why the step-up schedule exists
Tirzepatide acts on both the GIP and GLP-1 receptors, which is part of why it tends to produce more pronounced effects at a given dose than a GLP-1-only molecule. It is also why gradual increases matter: gastrointestinal tolerability generally improves the slower and steadier the ramp, and a rushed titration is where most avoidable discontinuations come from.
The most common operational mistake is treating the schedule as permission rather than a plan: moving someone up because four weeks have passed and the system allows it, rather than because a check-in has actually confirmed they are ready for the next strength.
Building a titration pathway that holds operationally
A workable pathway puts a real check-in in front of every step-up, not just the first one. That check-in can be a short clinical review, a structured questionnaire, or a brief consultation, but it needs to confirm tolerability and rule out red-flag symptoms before the next strength is dispensed, with a clear record of who approved the move and why. This is the kind of structure a service built around GLP-1 weight management prescribing needs from day one, not as an afterthought once volumes grow.
In practice that means a small, repeatable sequence rather than a bespoke decision each time:
- Baseline assessment before the first 2.5mg dose
- Structured check-in around week four, before the first step-up
- The same check-in before every subsequent increase
- A default hold-or-extend rule if side effects haven't settled
- A documented maintenance dose once a patient reaches a strength that suits them
A titration schedule is not a calendar. It's a series of individual decisions, each one needing its own evidence that the last dose was actually tolerated.
What to monitor at each step, not just at the start
Mild gastrointestinal symptoms, nausea, reduced appetite, occasional loose stool, are generally expected during titration and usually settle within the first weeks at a given dose. Red flags are different: severe or persistent abdominal pain, repeated vomiting, or signs consistent with pancreatitis or gallbladder problems should pause any planned step-up and prompt prescriber review, in line with the product's MHRA-approved summary of product characteristics.
Clinics running more than one GLP-1 or GIP/GLP-1 product also need to resist treating one escalation protocol as universal. The strengths, step sizes and typical tolerability profile differ by molecule, which is one reason our piece on Wegovy dose escalation sets out a separate schedule rather than a shared one.
When to pause, extend, or step back a dose
A sound pathway has a default policy for holding at a dose rather than auto-advancing, and for stepping back down a strength if side effects were significant, with both decisions sitting squarely with the prescriber and documented every time they're made.
- GI symptoms that haven't settled by the planned step-up date
- A patient requesting more time at the current strength
- A missed dose that may call for re-titration consideration under the SmPC guidance
- A new comorbidity or medication change that needs closer monitoring first
- Any red-flag symptom reported since the last check-in
The step-up date on the schedule tells you when an increase is allowed, not when it's a good idea.
Documentation that would survive a GPhC or CQC look
Each step-up decision should be traceable after the fact: who reviewed the patient, what they reported, and why the increase, or the hold, was approved. That traceability sits at the overlap of GPhC standards on safe and effective prescribing and CQC's expectations around safe-care records under its single assessment framework.
The dosing record only tells half the story unless it is tied to supply. For clinics sourcing tirzepatide through a mixed or compounded supply model, as discussed in our piece on GLP-1 dispensing, the record needs to show exactly which product, strength and batch was dispensed at each step, not just the dose the prescriber intended.
Where a dispensing partner fits in a titration pathway
PExpo stocks the full Mounjaro dose range as separate SKUs and dispenses the exact strength a check-in has approved, with batch and strength genuinely traceable against the clinical record rather than reconciled afterwards from a spreadsheet.
That also protects the pathway when a hold or extension is needed: supply doesn't get stuck if a patient needs to stay on a given strength longer than the default schedule assumed. If you're weighing how this fits alongside an injectable-to-oral GLP-1 pathway, our clinic page and pricing set out how the dispensing side plugs in.
A Mounjaro service that holds up at scale treats every step-up as a decision worth its own evidence, not a milestone that happens on schedule by default. Get the check-ins, the hold-or-extend rule and the dispensing record right, and the titration pathway looks after itself. For the supply side of a wider GLP-1 service, see our note on the UK GLP-1 supply chain, or get in touch to talk through how PExpo's dispensing layer fits your pathway.
Frequently asked questions
How long does full Mounjaro titration take?
Reaching the highest licensed dose from a standing start typically takes around five months, since each step-up is spaced at least four weeks apart and some patients need longer at a given strength. The exact pace is set by the prescriber based on tolerability, not a fixed timetable.
What's the Mounjaro starting dose?
Mounjaro is usually started at 2.5mg once weekly, a dose intended to let the body adjust rather than to produce significant weight loss on its own. Most of the therapeutic effect builds once a patient has stepped up to 5mg and beyond, under prescriber discretion.
Does every patient need to reach the highest Mounjaro dose?
No. Some patients tolerate side effects well and do fine on a lower maintenance dose, and the prescriber may choose to hold them there rather than push to the top of the range. The schedule sets a ceiling, not a target everyone has to hit.
